Intelligent Design and Imaginary Worlds in Cost-Effectiveness Claims: An Overview of Commentaries in INNOVATIONS in Pharmacy from July 2016 to February 2017 by Langley, Paul C
Volume 8 | Number 1 Article 22
3-9-2017
Intelligent Design and Imaginary Worlds in Cost-
Effectiveness Claims: An Overview of
Commentaries in INNOVATIONS in Pharmacy
from July 2016 to February 2017
Paul C. Langley
University of Minnesota, langley@maimonresearch.com
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Langley PC. Intelligent Design and Imaginary Worlds in Cost-Effectiveness Claims: An Overview of Commentaries in
INNOVATIONS in Pharmacy from July 2016 to February 2017. Inov Pharm. 2017;8(1): Article 22. http://pubs.lib.umn.edu/
innovations/vol8/iss1/22
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                        2017, Vol. 8, No. 1, Article 22                       INNOVATIONS in pharmacy   1 
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Paul C Langley, PhD, Adjunct Professor, University of Minnesota 
 
 
 
Abstract 
Over the past 30 years, thousands of modeled cost-effectiveness studies have been published. Whether this effort has been worthwhile 
is debatable. For supporters of modeled cost-effectiveness studies, this effort has been worthwhile because the modeled claims are 
intended to inform health care decision makes. To opponents, the effort is seen as largely a waste of time because the claims are 
typically non-evaluable. Rather than subscribing to the standards of normal science in its focus on hypothesis testing through 
experimentation and replication, opponents have viewed practitioners in health technology assessment as being content to develop 
imaginary worlds with no thought to their role in practical decision-making. Given this ongoing commitment to constructing imaginary 
worlds, the purpose of this commentary is bring together the various commentaries, together with supporting publications that have 
appeared in INNOVATIONS in Pharmacy since mid-2016. This is in response to requests from faculty and graduate students at the 
College of Pharmacy, University of Minnesota for an overview of the arguments presented to date in support of a new research program 
that rejects imaginary constructs in favor of credible, evaluable and replicable claims to support formulary decision making.   
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Introduction 
Over the past nine months, 22 commentaries published in 
INNOVATIONS in Pharmacy have pointed to the lack of 
credibility in modeled or simulated claims for the clinical 
benefit and cost-effectiveness of pharmaceutical products and 
devices. This lack of credibility stems from the construction of 
long-term or lifetime models of interventions in chronic 
disease states. The hallmark of such models is that the claims 
made are impossible to evaluate. The exemplars are the so-
called ‘reference case’ models, which mandate the 
construction of lifetime cost-per-quality adjusted life year 
(QALY) claims for hypothetical treatment cohorts. Claims for 
competing products which capture a time horizon extending 
for twenty, thirty or more years, are impossible to evaluate; 
they are immune to failure. Models which fail to generate 
evaluable claims have been characterized in these 
commentaries as imaginary worlds 1 . The health care decision 
maker has no idea whether these claims are right or even if 
they are wrong, and, of course, they will never know.  
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Clearly, decision makers must be aware that such modeled 
claims are impossible to assess. Even so, guidelines issued by 
number of agencies mandate or suggest manufacturers submit 
non-evaluable modeled or simulated imaginary cost-
effectiveness claims. These guidelines have been reviewed in 
the commentaries and supporting articles: 
 
• National Institute for Health and Care Excellence 
(NICE) in the UK2 
• Health Quality and Information Authority (HQIA) in 
Ireland 3 
• Pharmaceutical Benefits Advisory Committee (PBAC) 
in Australia 4 
• Haute Authorite de Santé (HAS) in France 5   
• Dutch National Healthcare Institute (ZN) 6 
• Pharmaceutical Management Agency (PHARMAC) in 
New Zealand7 
• Institute for Quality and Efficiency in Health Care 
(IQWiG) in Germany8  
• European Network for Health Technology assessment 
(EUnetHTA) 9 
• Academy of Managed Care Pharmacy (AMCP) in the 
US10 
Indeed, the Canadian Agency for Drugs and Technologies in 
Health (CADTH) has gone so far in its latest draft for the 4th 
edition of it guidelines released in October 2016 to make 
explicit its commitment to the construction of imaginary 
worlds and to put the scientific method to one side:  ‘Economic 
evaluations are designed to inform decisions. As such, they are 
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distinct from conventional research activities, which are 
designed to test hypotheses’ 11. 
 
This notion of ‘informing decision makers’ through the 
construction of imaginary claims for competing 
pharmaceutical products can, in fact, be traced back over the 
past 30 years with a number of publications supporting cost-
effectiveness analyses, to include the seminal Drummond et al 
textbook on health technology assessment 12 13 14. 
Unfortunately, the notion of ‘informing’ decision makers 
through constructing evidence to support cost-effectiveness 
claims opens the floodgates for competing imaginary worlds. 
Decision makers, even if they engage external reviewers to 
examine the ‘reality’ of competing models, will be faced with 
competing claims with each model justified in terms of its 
conformity to the model builders (or the commissioned model 
builders) perception of a future reality. The result is that over 
the past 30 years hundreds (if not thousands) of non-evaluable 
claims for product cost-effectiveness have been published. 
This is not, however, a blanket condemnation of health 
technology assessment, rather a rejection of those activities 
which have supported the construction of decision model 
claims which are non-evaluable. To separate the wheat from 
the chaff requires a commitment to science as an 
‘investigation of nature, based on the construction of 
empirically verifiable theories and hypotheses’.  
 
This commitment to the construction of imaginary claims for 
competing pharmaceutical products looks set to continue. 
There is no evidence that health technology assessment 
agencies or professional groups such as the AMCP, the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) or the EUnetHTA are prepared to reject 
imaginary non-evaluable cost-effectiveness claims, 
irrespective of whether these claims are expressed in cost-per-
QALY terms or other measures of health impact 15 16. These 
groups seem prepared to continue to be ‘informed’ through 
the construction of imaginary worlds. It could of course be 
argued that decision makers are aware of the constructed 
nature of the cost-effectiveness claims that are presented yet 
put them to one side, preferring instead to focus on the 
evidence from randomized clinical trials (RCTs) as the critical 
input to formulary positioning and pricing. If so, then it is 
difficult not to conclude that the effort put into promoting the 
construction of imaginary worlds over the past 30 years has 
been largely wasted.  
 
This commentary has been written in response to requests 
from faculty and graduate students in the Program in Social 
and Administrative Pharmacy at the University of Minnesota 
for an overview of the 22 commentaries published since July 
2016. Other commentaries will follow. Given the material 
covered, it was considered to be useful to look back and 
consolidate the arguments made in support of the scientific 
method for cost-effectiveness claims. This focus is reflected in 
the use of the term ‘intelligent design’ in the title to this 
commentary. The intent here is twofold: on the one hand to 
emphasize the importance of distinguishing science from 
pseudoscience (or, as Pigliucci would describe it, bunk) and on 
the other as a caution that claims for ‘realism’ in model 
structure and assumptions that accompany the construction of 
long-term or lifetime models are no more ‘intelligent’ that 
those claims for intelligent design (a.k.a. creationism). Unlike 
Dawkins’ ‘blind watchmaker’, the various of Paley’s ‘skilled 
watchmakers’ are known; they not only publish but  their 
activities are endorsed by professional groups such as the 
AMCP and ISPOR in their creation of unevaluable claims 
through modeled or simulated imaginary worlds17 18 19 .  The 
concern is that after 400 years of the acceptance of the 
scientific method, it is a moot point as to whether or not the 
many advocates of constructing imaginary worlds to inform 
decision makers recognize the disconnect between their 
advocacy of imaginary worlds and the standards of normal 
science.20.  
 
The Invention of Science 
There is no lack of evidence for the claim that the late 16th 
century and the 17th century (from Brahe’s nova of 1572 to 
Newton’s Opticks of 1704) witnessed a profound 
transformation; a change that Wootton has described as the 
‘invention of science’. The new science of the 17th century, 
what we may now call the Scientific Revolution was 
characterized, again as described by Wootton, by a 
preoccupation with the systematic employment of the test of 
experience, observation and experimentation. For our present 
purpose, the key point is that the revolution of the 17th century 
presented a challenge to and eventual overthrow of 
Aristotelian authority. Experimentation replaced an appeal to 
authority as witnessed in the motto of the Royal Society 
(founded 1660; Royal Charter 1662): nullius in verba (take no 
man’s world for it’).21. As stated on the Royal Society website, 
this motto ‘is an expression of the determination of Fellows to 
withstand the domination of authority and to verify all 
statements by an appeal to facts determined by experiment’22.  
 
Whether a scientific revolution actually occurred has been 
challenged by what has been described as the relativist school, 
in particular the strong program and the advocacy of 
equivalence in maintaining that  the ‘content’ of science, not 
just the organization, values and activities of scientists, can be 
explained sociologically through the ‘principle of symmetry’. 
Whether knowledge claims are sustained or not, relativists 
would maintain that it is illegitimate to prefer one explanation 
over another just because one is supported by evidence. 
Experimentation and hypothesis testing are not the only way 
of coming to grips with reality; a position presumably 
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subscribed to by CADTH.  Evidence, in Wootton’s summary of 
the relativist position, is never discovered ‘it is constructed 
within a social community … the success of a scientific research 
program thus depends on not its ability to generate new 
knowledge but to mobilize the support of a community’. 
Science is about ‘rhetoric, persuasion and authority’.  
 
For our present purposes, the relativist position, in particular 
its subscription to constructed evidence is important in the 
advocacy and acceptance of models or simulations that reject 
the scientific method and support non-evaluable product 
claims as decision criteria. For those readers who remain 
unconvinced then a Wikipedia reference ‘scientific method’ is 
a useful starting point 23. In the commentaries published to 
date this relativist position (it might even be described as 
postmodern) has been assessed, first, in the various 
commentaries that have reviewed the health technology 
assessment guidelines published in the US by the AMCP, the 
UK, New Zealand, Australia, The Netherlands, France, 
Germany and those proposed by EUnetHTA for the European 
Union 24 25 26 27 28 29 30 31. A separate review of the Irish 
guidelines was published in Current Medical Research and 
Opinion 32. Reference should also be made to a series of papers 
on the status of modeled claims commissioned by the Journal 
of Medical Economics in late 2015  33 34 35 36 37. The purpose of 
these last commissioned papers was to argue that the only 
acceptable modeled claims for costs and outcomes are those 
that are testable and can be validated in a timeframe that is 
acceptable to a formulary committee. The four papers 
explored the methodological issues in validation, the UK 
experience with NICE, the questions a formulary committee 
should ask of modeled claims, and the role of Big Data in 
validating modeled claims. 
 
The common theme in these commentaries is that 
manufacturers and others making formulary submission are 
asked to create imaginary worlds to support, typically in 
chronic diseases, competing clinical and cost-outcomes claims. 
In all of these cases, the exemplar is the NICE lifetime cost-per-
QALY ‘reference case’. The key requirements are a modeled or 
simulated claim that includes: (i) all direct health effects; (ii) a 
cost-utility-analysis with full incremental analysis; (iii) a time 
horizon long enough to reflect all important differences in 
costs or outcomes between the technologies being employed; 
and (iv) health effects to be expressed in QALYs with the EQ-
5D as the preferred measure. In practice, this is a blueprint for 
constructing (outside of short-term acute interventions or 
possible end-of-life interventions) long-term or lifetime 
models with outcome claims that are not intended to be open 
to evaluation and replication. 
Demarcation: Pseudoscience 
There is an ongoing debate in the philosophy of science 
literature over the question of demarcation; how do we 
distinguish science from non-science, including between 
science and pseudoscience? For Popper, the issue was clear 
cut. The necessary and sufficient condition for demarcation is 
the ability to falsify claims 38 39. Unlike verification, ‘statements 
or systems of statements, in order to be ranked as scientific, 
must be capable of conflicting with possible or conceivable 
observations’. This does not mean that single instances where 
a theory is falsified would lead to its rejection; scientific 
progress is not as neat as that. However, the point remains: 
theories must be judged empirically. If they fail the test of 
generating evaluable claims then they are either non-scientific 
or fall into the pseudoscience category. Unfortunately, as 
lifetime cost-per-QALY or life years saved models 
demonstrate, there is still a willingness to accept 
pseudoscience and, as Pigliucci argues, superstitious belief in 
general.  
 
Unfortunately, despite assertions that the construction of 
claims through imaginary worlds can ‘inform’ decision makers, 
the fact that the models lack evaluable claims put them in the 
category of pseudoscience. As such, lifetime-cost-per-QALY 
models share the platform with intelligent design rather than 
with natural selection. While we might agree that there is a 
continuum between ‘hard’ and ‘soft’ sciences, the common 
feature is the construction of empirically verifiable theories 
and hypotheses’. Pigliucci describes this as a ‘trinity’ that 
underlies all scientific activities: a commitment to dealing with 
natural phenomena and processes; a commitment to dealing 
with coherently conceptual constructs  in the form of theories 
or hypotheses; and a commitment to assessment through 
experimentation and systematic observation. These three 
elements are not present in the construction of imaginary 
worlds. Rather, models and simulations that are considered to 
be sufficient in their representation of reality that the claims 
made necessarily follow 40 .   
 
Relevance: Quality Adjusted Life Years 
As well as pointing to the uncritical acceptance of the 
reference case as the standard for modeled or simulated 
claims, the commentaries have also pointed to the limitations, 
both methodological and practical, of focusing on QALYs as the 
exemplar outcome measure in its ability to capture both 
morbidity and mortality 41. Despite the popularity of QALYs as 
the ‘gold standard’ outcome measure among academic 
audiences, professional groups and a number of single payer 
health care systems, there is no evidence that health care 
systems have put in place policies to collect systematically 
utility scores to support, if presented in evaluable terms, cost-
per-QALY claims either through experimentation or 
observation.  
 
The commentaries also point out that in the US there has been 
little effort put towards agreeing on the need for, let alone the 
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construction, of a reference standard for QALYs. First, there is 
no agreement on whether or not it is even possible to agree 
on a reference standard given the diversity and incompatibility 
of the various QALY measures; a situation that is no different 
to the plethora of patient reported outcomes instruments that 
characterize various disease states. Second, it is doubtful, even 
within a health care system whether agreement could be 
reached on the choice of QALY instrument and the preferences 
for the defined health states. Third, unless a QALY metric is 
established as a process or outcomes measure for quality 
assessment, there is little chance that any health care system 
would invest resources in capturing QALYs from a specific 
instrument on a regular basis. Fourth, the chance that a QALY 
quality metric would be mandated in the US is effectively zero. 
This is made abundantly clear in the Affordable Care and 
Patient Protection Act (2010) which requires that the Patient 
Centered Outcomes Research Group (PCORI) exclude 
discounted cost-per-QALY or similar discounting measures and 
threshold values for priority setting in health care 42.   
 
Overall, the commentaries conclude that it is doubtful, that the 
great expectations for QALYs could ever be realized outside of 
reference case imaginary worlds, or the willingness of decision 
makers to suspend belief in the standards of normal science, 
and accept lifetime cost-per-QALY claims as decision criteria. 
Unless, therefore, a case can be made for short-term and 
evaluable QALY claims, there seems little scope for QALYS, and 
associated cost-per-QALY claims, as inputs to formulary 
decision making. Perhaps, as Pip says to Estella, it has been ‘a 
vain hope and an idle pursuit’43.   
 
One exception to this rejection of QALYs in the US are the 
activities of the Institute for Clinical and Economic Review 
(ICER), a research organization. The ICER has adapted the NICE 
model to a US environment and has produced a succession of 
reports that have applied a reference case standard for 
lifetime (or long term) cost per QALY models to threshold 
willingness-to-pay value based pricing claims. Two of these 
reports have been reviewed in these commentaries pointing 
to their lack of scientific credibility in generating unevaluable 
simulated claims 44  45 46 47. The first of these reviews explored 
alternative modeled claims for Entresto, an angiotensin 
receptor neprilysin inhibitor, versus the standard of care with 
an ACE inhibitor in patients with chronic heart failure. Two 
models were compared: a lifetime cost-per-QALY model and a 
3-year cost and budget impact model. The primary reason for 
this review was the puzzling feature that for a product which 
is over 120 time as expensive compared to the standard of care 
(Entresto $380 per month vs. ACE inhibitor $3 per month) the 
modeled claim can be made that the product is, in willingness 
to pay terms, cost-effective. The analysis illustrates that, 
perhaps not surprisingly, different models can generate quite 
different perspectives on the presumption of ‘cost-
effectiveness’. The commentary concluded that if modeled 
claims are to be useful for formulary decision making, then we 
need to eschew ‘black box’ models with non-evaluable claims 
in favor of those models that yield credible, evaluable and 
replicable claims that can support defensible product 
placement and pricing decisions. The second and more recent 
of these reviews is  the ICER January 2017 report on disease 
modifying therapies (DMTs) in multiple sclerosis. The review 
concluded that the claims presented for the competing DMTs 
are not credible, evaluable or replicable.  
 
The objection to lifetime cost-per-QALY models applies also 
the models that have put QALYs to one side in favor of 
measures that have focused on more ‘realistic’ endpoints such 
as life years saved or other long-term disease specific clinical 
criteria. Unless these claims are evaluable they face the same 
objections raised in respect of QALYs: the claims are not 
credible and should be rejected. This is pointed to on the 
review of the German IQWiG guidelines where an efficiency 
frontier that attempts to capture lifetime costs and benefits 
has no more scientific merit than the application of the NICE 
reference case 30. 
 
Absence: Compliance and Pricing Strategies 
In these commentaries the question has been raised as to why, 
in the construction of imaginary worlds, simulations have 
typically failed to take account of (i) patterns of adherence and 
persistence to medications and (ii) a commitment by 
pharmaceutical manufacturers to a policy of sustained price 
increases. Irrespective of the lack of scientific merit in 
generating unevaluable claims, both issues undermine the 
lifetime perspective.  
 
Evidence points overwhelmingly to the lack of adherence and 
persistence with medications. Within as short a period as two 
years there are a number of disease areas where less than one-
third of patients continue to be fully adherent to their 
medications or have discontinued therapy altogether. If this is 
the case then modeled claims that do not accommodate this 
perspective, or which understate the lack of long-term 
compliance, are of little interest to decision makers. This, 
unfortunately, opens Pandora’s box: would manufacturers 
support modeled claims and the underwriting of a protocol to 
assess those claims when the evidence would suggest that for 
the majority of patients the perceived clinical benefits are only 
short term or transitory in nature? From the manufacturer’s 
perspective, of course, it is not compliance behavior per se that 
is of interest but maintaining and increasing market share 
primarily by encouraging patients and physicians to initiate 
therapy. Manufacturer supported policies to improve 
compliance behavior are, it appears, of secondary interest. As 
long as new entrants at least balance out those discontinuing 
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therapy, market share is maintained. Any question of 
continuing benefits to patients is put to one side.  
 
Policies by manufacturers for sustained annual or semi-annual 
price increases, with the percentage increase often in the 
double digits, also casts doubt on lifetime models. These 
models, while discounting lifetime costs and outcomes, take 
no account of long-term price increases and their contribution 
both to annual drug costs and other direct medical costs. 
Failure to consider the implications of policies by 
manufacturers to regularly increase the prices of 
pharmaceuticals on a semi-annual or annual basis means that 
claims for cost-effectiveness based on current prices are out-
of-date within a few months. Indeed, if the strategy is to 
publish cost-effectiveness lifetime non-evaluable claims, then 
the claims are out of date even before the commissioned 
‘marketing’ paper is published. This issue has been raised in 
the commentaries, again with specific reference to the two 
ICER evaluations 44 45. In the case of multiple sclerosis, 
reference was made to a recent study by Hartnung et al, of the 
trend in annual drug costs for nine disease modifying therapies 
(DMTs) from 1993 to 2014 48.  Apart from the fact that DMT 
costs are two to three time bigger in the US than other 
countries, the principal finding is that DMT costs have 
accelerated well beyond inflation and substantially above 
rates for drugs observed in a similar biologic class. Annualized 
change in the cost of the nine DMTs in the evaluation ranged 
from 35.7% for glatiramer acetate to 7.9% for fingolimod. Four 
of the DMTs had annualized cost increases above 20% and four 
with annualized price increases between 13.0% and 16.8%. 
Natalizumab, for example, although being withdrawn briefly 
from the market between February 2005 and June 2006, 
increased in cost from $25,850 in 2004 to $64,233 in 2013 or 
an annualized increase of 16.2%. In terms of the overall ‘costs’ 
of care for commercially insured MS patients, a comparison of 
charges between 2006 to 2011 pointed to the continuing 
significant impact on total costs of the charges associated with 
drug costs (52.6% in 2011) 49 . At the same time, the increase 
for DMTs far outstripped the charges for other medical 
services (95.7% vs. 32.4%).   
 
Progress: Replication of Imaginary Claims 
If competing claims for pharmaceutical products are non-
evaluable then it puts to one side one of the critical features of 
progress in science: the ability not only to empirically assess 
claims but to replicate those claims across, in this case, target 
patient populations. This is true both of clinical claims, in 
particular comparative clinical claims based upon indirect 
comparisons, as well as cost-outcomes and budget impact 
claims.  
 
In health technology assessment the evidence base is, all too 
often, somewhat scanty. Guidelines for formulary submission 
typically put the question of replication of clinical claims to one 
side even though there is considerable disquiet over the 
inability to replicate phase 2 and phase 3 RCT claims 50 51 52. 
This omission is compounded when non-replicable claims are 
embedded in models or simulations to support cost-outcomes 
claims, extrapolating over the long-term or the lifetime of an 
imaginary treatment cohort. The only way to overcome this 
question of ‘belief’ in comparative clinical claims is, as 
suggested here, to put claims in evaluable terms. 
 
Publications: Imaginary Worlds  
In commentaries published to date, the willingness of editors 
of three of the leading health technology assessment 
periodicals to publish non-evaluable claims, typically lifetime 
cost-per-QALY models, has been evaluated. The three journals 
are Value in Health, Pharmacoeconomics and the Journal of 
Medical Economics 53 54 55. In each case a systematic review 
was undertaken of articles publish in the period January 2015 
to December 2015. Each of the studies was judged against four 
criteria:  (i) Is the model capable of generating evaluable 
claims? (ii) did the author(s) attempt to generate evaluable 
claims? (iii) did the author(s) suggested how the claims might 
be evaluated? and (iv) did the author(s) caution readers as to 
the implications of generating non-evaluable clams for the 
credibility of the analysis? In the case of Value in Health, 16 
papers were identified. Of these 14 presented a cost-per-QALY 
analysis, with 9 presenting their claims for comparative 
effectiveness in a lifetime cost-per-QALY framework. With the 
focus of the assessment on whether or not these studies 
generated testable claims, none of the studies met this 
standard. The result for Pharmacoeconomics was the same. A 
total of 31 studies were evaluated, including 14 research 
articles, 8 systematic reviews and 9 reviews. Although the 
majority of the studies met recommended standards for cost-
effectiveness analysis, none met the standards of normal 
science. They were best categorized as imaginary worlds or 
thought experiments. The same conclusion was reached for 
the Journal of Medical Economics. A total of 32 studies were 
identified. None of the studies presented their claims or 
projections in an evaluable form and none suggested how they 
might be evaluated. None met the standards of normal 
science. The claims made for cost-effectiveness were either 
impossible to verify, or if potentially verifiable, were not 
presented in an evaluable form. Indeed, in the case of the 
Journal of Medical Economics of the 32 studies, 30 were 
apparently funded by pharmaceutical manufacturers and 29 of 
the constructed simulations favored the manufacturer’s 
product. 
 
It is proposed to continue these evaluations of published 
studies and to extend the analysis to other journals as part of 
this ongoing commentary series. A major focus will be the 
extent to which unevaluable modeled comparative claims for 
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pharmaceutical products should be seen as contributions to 
the marketing and formulary acceptance of products when the 
study is underwritten by the manufacturer.  
 
As well as these reviews of leading journals, a separate 
assessment was also undertaken of cost-effectiveness studies 
and their assumptions in diabetes mellitus and atrial 
fibrillation 56 57. In the first commentary reviewing diabetes 
mellitus models claims presented are all too often either 
immune to failure or are presented in a form that is non-
testable. As such they fail to meet the key experimental 
requirements of falsification and replication. The second 
commentary the focus was on whether not the modeled 
claims for new oral anticoagulants (NOACs) met the standards 
of normal science in supporting falsification and replication. A 
systematic and consensus review by the authors identified 23 
cost-utility NOACs evaluations along with four single 
technology appraisals undertaken by the National Institute for 
Health and Care Excellence (NICE) in the UK. None of the 
studies presented projections or claims in a form suitable for 
empirical evaluation. None could support falsification or 
replication. They failed the standards associated with the 
scientific method. 
 
Progress: Minnesota Proposed Guidelines58 
The primary purpose of the Minnesota guidelines, with the 
first version published in July 2016 and a revised second 
version published on the College website in December 2016, 
and detailed in accompanying commentaries, was to revisit an 
earlier guideline for formulary submissions developed in 2005 
for the WellPoint (now Anthem) health system 59 60 61 62. Under 
the guidelines manufacturers submitting proposals for either 
new products or for products being revaluated as part of 
disease area and therapeutic class reviews, were required to 
present evaluable claims together with a study protocol 
detailing how the claims were to be evaluated and reported 
within a meaningful time frame. The proposed timeframe was 
two years. Until the claims were reported back, any pricing and 
formulary position would be provisional and in line with the 
product that was most likely to be replaced in practice. Non-
evaluable modeled or simulated claims were to be rejected. 
 
The revised December 2016 version 2.0 of the Minnesota 
proposed  guidelines took into account the genetic targeting 
of therapies under next generation sequencing (NGS). It was 
considered that, with the dearth of clinical trials to support 
targeting therapies for products, which were likely to be off-
label, the requirement for protocols to support evaluable 
claims was important. The question of NGS and its implications 
for formulary evaluations was explored in two commentaries  
63 64.  The first of these commentaries considered (i) the 
evidentiary standards for the evaluation of an NGS test and 
comparator tests and (ii) identified questions that a formulary 
committee should address in submissions made for a test in 
health care systems. A critical issue was not only comparative 
claims for the test against the standard of care and comparator 
tests, but the assessment of test performance for the 
identified treatment pathways where mutations or variants 
are linked to recommendations for therapy options. The 
second commentary considered how NGS may disrupt not only 
the accepted process of drug development but also the 
hurdles a drug manufacturer would be expected to face in 
securing formulary approval and a possible premium price for 
new compounds. This was  characterized as a process of 
creative destruction, where adoption of NGS in personalized 
medicine sets in train a process of ongoing product review. A 
mechanism driven by continuing modifications and extensions 
to NGS platforms as our understanding of the role of mutations 
and mutation load in therapy choice expands.   
 
In proposing protocols for formulary claims evaluations, the 
Minnesota guidelines present a checklist for assessing whether 
or not the claims presented are potentially credible, evaluable 
and replicable. There are a number of guidelines proposed in 
the literature, such as the ISPOR sponsored CHEERS guidelines, 
which do not meet these requirements 65  . In a recent 
commentary the Assessment of the Validation Status of 
Health-Economic Decision Models (AdViSHE) checklist for 
decision models was evaluated  66 . This new checklist which is 
intended to address the perceived need for a tradeoff between 
confidence in a decision model and the need to allocate 
resources by developers and payers to validating the model, 
does not address the issue of credibility, evaluation and 
replication of claims. The checklist fails the standards of 
normal science. Apart from the absence of a commitment in 
the AdViSHE checklist to the modeling of claims that are 
evaluable and replicable, the validation check list makes no 
allowance for a product pricing strategy that may commit a 
manufacturer to regular and substantial annual or semi-annual 
product price increases. Indeed, product-pricing assumptions 
are conspicuous by their absence.  
 
Next Steps:  Towards a Credible Research Program 
As well as presenting a critique of current standards and 
processes for formulary evaluation, the various commentaries 
also considered the key elements in developing a research 
program in formulary submission evaluations that met the 
standards of normal science. The key here was the 
development of credible, evaluable and replicable claims to 
support pricing and formulary placement decisions. After over 
30 years, however, it is unlikely that the current commitment 
by academic groups, professional associations, consultants 
and manufacturers to the construction of imaginary worlds will 
be readily abandoned. These groups have a considerable 
investment in constructing lifetime cost-per-QALY, viewing 
these as an essential input to formulary decisions; or, at least, 
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a worthwhile marketing tool to demonstrate the superiority of 
a sponsor’s product. Many will be affronted by the label 
‘pseudoscience’, even if they recognize that the claims made 
are non-evaluable. Many will, no doubt, continue to argue that 
while constructed claims are not consistent with the standards 
of normal science, these imaginary projections have a role to 
play in ‘informing’ decision makers. Presumably, in adopting a 
relativist (indeed a postmodernist) position means accepting 
that a lifetime cost-per-QALY threshold claims is to be viewed 
as just as valid as a daily astrological forecast or an evaluable 
short-term cost-outcome claim in informing decision makers. 
 
For relativists, as Wotton points out, there is no concept of 
progress in science 20. Relativists view science as entirely a 
social construction. Knowledge is whatever we choose it to be. 
There is no basis for demarcating good from bad science; good 
‘information’ from ‘bad’ information’. Evidence to support 
competing theories is irrelevant. Reality does not constrain 
belief 20. A historical case for the ‘invention of science’ in the 
late 16th and the 17th centuries tracing out the growing 
acceptance, the path-dependence, of the role of experimental 
programs of testing, refining and rejecting theories is beside 
the point. As Wootton emphasizes, relativists (or those 
accepting cognitive egalitarianism) cannot think historically 20 . 
This does not mean, of course, that one would necessarily 
embrace a strictly (and naïve) realist position. Even so, there 
remains the key question of demarcation and the role of 
experimentation. It is experimentation that divides science 
from pseudoscience and science from non-science. For 
experimentation and systematic observation to play their role, 
we require claims that are empirically evaluable.    
 
Unfortunately, as much as interested parties may mount a 
rearguard action in support of non-evaluable claims for clinical 
and cost-effectiveness outcomes, the fact remains that 
modeled or simulated claims can fail. The problem in health 
technology assessment is that the modeled or simulated 
claims are typically immune to failure. If this argument is 
accepted, then there appears no option but to abandon 
constructed, non-evaluable claims in favor of a research 
program that meets the standards of normal science. After 30 
years, when many have devoted a considerable part of their 
academic life to developing standards, promoting and 
publishing modeled or simulated non-evaluable claims, many 
of increasing mathematical complexity, their lack of relevance 
for decision making may come as a blow. Unfortunately, the 
last 30 years have witnessed the willingness of practitioners, 
supported by professional groups such as the AMCP and 
ISPOR, together with many academic research centers, to put 
the standards of normal science to one side in encouraging the 
construction of imaginary worlds.   
 
 
Conclusions 
Unless claims are evaluable and replicable in target patient 
populations, we lose any notion of scientific progress in our 
ability to develop models or simulations to support a greater 
understanding of the anticipated impact of new products and 
claims for comparative cost-effectiveness. This sets the stage 
for a progressive research program. The process of conjecture 
and refutation is central to the scientific method. Our 
understanding proceeds through the continuous process of 
empirically evaluating claims. This process may lead to a 
modification, enhancement or even a rejection of the model. 
This feedback is an essential element and one, unfortunately, 
that is entirely absent if modeled or simulated claims are not 
evaluable. In this situation, the idea of progress is absent. 
Presumably, if we continue to subscribe to the current 
paradigm of modeled yet unevaluable claims, we can look 
forward over the next 25 years to an ever growing body of 
cost-per-QALY lifetime disease specific models that the 
authors believe ‘inform’ decision makers, yet which decision 
makers may quite reasonably reject in the absence of any 
predictive content. 
 
Some readers may find it odd that it is necessary to remind 
analysts in health technology assessment of the need to 
develop claims for the cost-effectiveness of pharmaceutical 
products and devices that meet the standards of normal 
science. Irrespective of the widespread and uncritical 
acceptance of constructed lifetime models in health 
technology assessment by the community of professional 
groups in health technology assessment as a viable and 
informative research program, this position must be 
abandoned. Embarrassment aside, a commitment to 
developing evaluable cost-outcomes claims is not asking for a 
radical departure from standards that apply in other areas of 
health technology assessment. There is, to give one example, 
an established literature evaluating the determinants of 
adherence and persistence behavior. Another example would 
be the use of retrospective data to evaluate comparative 
clinical claims and patterns of resource utilization. There are a 
growing number of accessible databases capturing not only 
administrative claims but integrating these with electronic 
medical records as well as web-based software to monitor and 
track patient outcomes through linking on-line patient 
reported outcomes with clinical profiles. These data provide 
ample opportunities to evaluate claims. As evidence for this, 
we can point to the nascent commitments to comparative 
effectiveness analysis. Although it is, doubtful if this program 
will meet its objectives given the issue of funding and the 
understandable reluctance, or at least wariness, of 
manufacturers to support such a research program. Even so, 
there is no excuse for not moving to evaluable claims. 
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Mainstream analysts in cost-effectiveness analysis are asking 
health decision makers to put the clock back, to take ‘their’ 
word for it. Over the last 30 years, we have witnessed the 
willingness of practitioners in health technology assessment, 
supported by the appeal by professional groups such as the 
AMCP and ISPOR, together with academic ‘modeling’ centers, 
to encourage and provide training in the construction of 
imaginary worlds. An appeal that mirrors the appeal to 
Aristotelian authority, which after some 1,500 years, took a 
century to overturn. The commentaries published over the 
past 10 months in INNOVATIONS in pharmacy are an attempt 
to overturn the existing technology assessment paradigm; to 
reject relativist reference case standards for non-evaluable 
claims in favor of a progressive research program. The 
hallmark of this program is to be to one side non-evaluable 
claims in clinical and cost-outcomes claims, focusing instead 
on models or simulations, which can generate feedback to 
health care decision makers. Whether it is sufficient to 
overturn the present technology assessment paradigm is an 
open question. 
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